BridgeMD
A Pragmatic Randomized Trial to Evaluate the Effect of Recombinant Herpes Zoster Vaccine on Major Adverse Cardiovascular Events and Dementia in Adults Aged 65 Years or Above
EU CTIS ID: 2025-524944-37-00
What this study is testing
This trial has two dual-primary objectives: 1) To evaluate the effect of Shingrix® on the risk of MACE, defined as a composite of hospitalization for non-fatal myocardial infarction, non-fatal stroke and cardiovascular death, in adults aged 65 years and older 2) To evaluate the effect of Shingrix® on the risk of new dementia in adults aged 65 years and older.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Age 65 years and above at the time of consent
- Informed consent form has been signed and dated
- Self-reported ability to understand written and spoken Danish or English
You likely can't join if
- The study has the following exclusion criteria (self-reporting): 1. A prior diagnosis of dementia 2. Chronic inflammatory rheumatic disease and concomitant immunosuppressive therapy 3. Prior herpes zoster vaccination
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.